GLIATECH INC
10-Q, EX-27.1, 2000-08-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: GLIATECH INC, 10-Q, 2000-08-14
Next: U S PHYSICAL THERAPY INC /NV, 10-Q, 2000-08-14



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                           4,937
<SECURITIES>                                    10,178
<RECEIVABLES>                                    3,665
<ALLOWANCES>                                        43
<INVENTORY>                                      5,812
<CURRENT-ASSETS>                                25,749
<PP&E>                                           6,162
<DEPRECIATION>                                   2,731
<TOTAL-ASSETS>                                  31,842
<CURRENT-LIABILITIES>                            4,731
<BONDS>                                              0
                                0
                                          0
<COMMON>                                            96
<OTHER-SE>                                      27,015
<TOTAL-LIABILITY-AND-EQUITY>                    31,842
<SALES>                                          7,035
<TOTAL-REVENUES>                                 7,278
<CGS>                                            1,165
<TOTAL-COSTS>                                    1,165
<OTHER-EXPENSES>                                 6,615
<LOSS-PROVISION>                                    17
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  (230)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              (230)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (113)
<EPS-BASIC>                                     (0.02)
<EPS-DILUTED>                                   (0.02)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission